Approaches to Patient Care in Optometry - Optometry Advisor
Oct 4, 2024 · An optometry student can learn a lot in a lab or clinical research setting, but their contact with patients will ultimately guide their clinical decision-making skills and shape their perspectives, according to Andrew Rixon, OD, FAAO, Diplomate (Glaucoma), this year’s recipient of the Vincent Ellerbrock Clinician Educator Award.
Myopia in Adults - Optometry Advisor
Nov 1, 2024 · Axial Elongation in Adult Myopia . Regular eye exams are important for all adults, particularly those experiencing myopia progression. During these visits, it is important for clinicians to measure axial length, due to its association with pathologic myopia. 3 An optical biometer can best measure axial length changes, but not all practices have one. . Among optometry practices that do utilize ...
Lens-Based Myopia Control: Know When to Treat and Expect Results
Dec 15, 2023 · Treatments were decided based on the results of this data analysis and patients were monitored every 3 to 6 months for progression, which was defined as 0.25 D or greater myopia spherical equivalent progression (as assessed with cycloplegic autorefraction) or greater than 0.10 mm axial elongation in 6 months. Children who showed progression while on one treatment, received a change in treatment.
Ocular Surface Disease Drugs Show Real-World Results
Jan 17, 2025 · Prior to launching perfluorohexyloctane, prescription dry eye treatments were aimed at reducing inflammation and increasing tear production. Even though targeting these areas can be beneficial, they do not specifically address the evaporative component of DED. 5 Perfluorohexyloctane, however, not only treats both the signs and symptoms of dry eye, but targets this element, which previous ...
Geographic Atrophy Management - Optometry Advisor
Jan 8, 2025 · Geographic Atrophy’s Effect on Vision . This advanced stage of dry AMD is characterized by an accumulation of drusen, a loss of photoreceptor cells, retinal pigment epithelium (RPE) changes, and retinal and choroidal atrophy, leading to distinct atrophic lesions in the macula that often increase with time. 3 Once GA begins, progression can be rapid and lead to poor patient outcomes.
Myopia Control Spectacles for Myopia Management - Optometry …
Dec 6, 2024 · Eye care professionals have come to understand the importance of not only correcting myopia, but slowing its progression within the last few decades; and while the US Food and Drug Administration (FDA) has approved contact lens therapies for treating the disorder, the agency has yet to approve any myopia control spectacles. Today’s “myopia boom” affects patients worldwide, worsening ...
FDA Alerts: New Optometry Drugs and Devices
Feb 20, 2024 · Drug Regulatory Updates. PL9643: Dry Eye Disease. Palatin Technologies, Inc. has received confirmation from the FDA regarding the acceptability of the protocols and endpoints for signs and symptoms of PL9643 in its phase 3 pivotal clinical trials for dry eye disease (DED). 1 The remaining phase 3 clinical trials, MELODY-2 and MELODY-3, include endpoints related to both signs and symptoms of ...
Weight Loss May Improve Ocular Health, But More Research Is …
Dec 1, 2023 · Research has demonstrated that obesity and overweight are significant risk factors for several ocular diseases, but can weight loss improve ocular health? With up to 51% of the US population projected to experience obesity by 2030, clinicians and patients can benefit from understanding the potential value weight loss has for improving glaucoma, diabetic retinopathy (DR), dry eye disease (DED ...
Optometry Advisor Redesign: New Look, Same Vision
Sep 12, 2022 · Optometry Advisor’s got a new look, but remains committed to the same high-quality clinical content and comprehensive research news updates.
Red Light Therapy Provides Myopia Control ... - Optometry Advisor
Nov 22, 2023 · As optometrists struggle with the demand created by an emerging myopia epidemic, repeated low-level red light therapy may provide an alternative to contact lens wear or atropine treatment for slowing axial progression and spherical equivalent refraction (SER). While the treatment has yet to receive US Food and Drug Administration (FDA) approval, it has demonstrated efficacy in clinical trials ...